Tanvex BioPharma, Inc. has announced the successful completion of its acquisition of Bora Biologics, based in Taiwan.
Bora Biologics is a subsidiary of Bora Pharmaceuticals, a premier international contract development and manufacturing organization (CDMO) specializing in complex oral solid dose, liquids, semi-solids and nasal sprays for pharmaceutical Rx and OTC products. Bora Biologics provides end-to-end and tailored development and manufacturing services to biologics developers.
Tanvex BioPharma, Inc. is a CDMO for biologics and a biosimilars products company. The company was founded in 2011 and is headquartered in Taiwan and San Diego, California.
Following this acquisition, Tanvex’s CDMO services will operate under the name Bora Biologics, continuing to be owned by Tanvex. The transition to Bora Biologics will not affect ongoing projects or operations, and clients can expect the same level of care they have come to rely on. Stephen Lam, Chief Executive Officer of Tanvex, will continue to lead the newly merged organization. All existing contracts and partnerships will be honored under the new brand. Financial terms of the deal were not disclosed.
According to data captured in the LevinPro HC database, this acquisition represents the second CDMO deal of 2025. There were 30 CDMO transactions announced during 2024, 21 announced during 2023 and 38 announced during 2022.
